Current and Emerging Treatments in the Management of Castration-Resistant Prostate Cancer

David Shapiro; Basir Tareen


Expert Rev Anticancer Ther. 2012;12(7):951-964. 

In This Article

Five-year View

We believe that within the next 5 years the treatment of CRPC will continue to evolve. If agents such as MDV3100 and radium-223 are approved by the FDA, we may see them first used in the patients who fail initial therapy and possibly in the chemotherapy-naive setting. The optimal sequencing for abiraterone and sipuleucel-T is yet to be determined, but many believe that if a product such as sipuleucel-T can be given earlier in the disease process, it may be more beneficial. Given the aging population in the USA and the recent push away from PSA screening in the USA, we may very well see an increase in the number of patients who progress to CRPC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.